Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.

Pathology, research and practice - 1 Jan 2024

Mollica Veronica, Tassinari Elisa, Santoni Matteo, Marchese Paola Valeria, Giunchi Francesca, Maloberti Thais, Tateo Valentina, Ricci Costantino, Rosellini Matteo, Marchetti Andrea, Fiorentino Michelangelo, Biase Dario De, Massari Francesco

Abstract excerpt

BACKGROUND: TERT promoter mutation is one of the most common genomic alterations in urothelial carcinoma (UC). Its prognostic role on patients' outcomes is still not clear. METHODS: We performed a single-center retrospective analysis on patients with advanced UC treated with platinum-based chemotherapy or immunotherapy to assess the presence of somatic TERT-124[C>T] and TERT-146[C>T] mutations and their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Platinum

Share to Telomerase

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 38103361
DOI: 10.1016/j.prp.2023.155008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.PMID 38103361Read ↗

A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.Semantic proximity Read ↗

Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinomaSemantic proximity Read ↗

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.Semantic proximity Read ↗

Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.Semantic proximity Read ↗

Emerging targets in upper tract urothelial carcinomas: the TERT gene.Semantic proximity Read ↗

Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.Semantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.Semantic proximity Read ↗

Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancerSemantic proximity Read ↗

TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance.Semantic proximity Read ↗

High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.Semantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.